You are here

Press Releases

lifeIMAGE announced today the release of Clinical Connector, powered by lifeIMAGE, a high-performance, scalable, and secure health care application. It connects patients to their care delivery ecosystem while simultaneously simplifying administrative burdens for caregivers. Clinical Connector was built from the ground up using U.S. and international standards to enable a growing and broad set of interoperability needs across clinical and non-clinical applications, including medical imaging platforms that can now share data seamlessly between clinicians and patients. In the interest of patient continuity, lifeIMAGE is making the Clinical Connector available to all clearinghouse users of the Radiological Society of North America (RSNA) Image Share pilot program, which is coming to a successful completion on March 31, 2018.

Recovery Force - a medical device company focused on enhancing circulation and accelerating recovery from surgery or injury through the use of its patented active compressions™ technology platform, announced today a collaboration with Mayo Clinic

MedSec LLC, a leading provider of cybersecurity solutions to the medical device and healthcare industry, announced today the appointment of Stephanie Domas as Vice President of Research. Among her responsibilities will be the introduction of MedScan, a new tool which allows hospitals to assess the cybersecurity status of the medical devices on their networks.

CLEW Medical, formerly known as Intensix, is launching its AI predictive-analytics platform to prevent life threatening complications in all care settings, using real-time data and machine learning technology. Already proven in the ICU, CLEW’s platform provides medical staff and healthcare administrators with actionable clinical, operational and financial insights to streamline medical care.

NewYork-Presbyterian and Walgreens are collaborating to bring convenient access to NewYork-Presbyterian’s world-class care through new telemedicine services, now available through Walgreens digital properties and at self-service kiosks at select Duane Reade drugstores in New York.  NewYork-Presbyterian, New York’s No. 1 hospital, is offering the telemedicine services as part of its NYP OnDemand suite of digital health services.

Once considered a futuristic technology on the distant horizon, 3D printing of medical devices, medications and human tissue is quickly becoming a promising reality. Patients have already benefitted from 3D printed medical products through access to personalized devices and innovative drugs that have led to significant health improvements. But the FDA is now preparing for a significant wave of new technologies that are nearly certain to transform medical practice. We're working to provide a more comprehensive regulatory pathway that keeps pace with those advances, and helps facilitate efficient access to safe and effective innovations that are based on these technologies.

The U.S. Food and Drug Administration today approved the FoundationOne CDx (F1CDx), the first breakthrough-designated, next generation sequencing (NGS)-based in vitro diagnostic (IVD) test that can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type. The Centers for Medicare & Medicaid Services (CMS) at the same time proposed coverage of the F1CDx. The test is the second IVD to be approved and covered after overlapping review by the FDA and CMS under the Parallel Review Program, which facilitates earlier access to innovative medical technologies for Medicare beneficiaries.

Accurate Neuromonitoring, a leading Intraoperative Neuromonitoring (IONM) provider offering functional guidance to surgeons through the use of electrophysiological methods that help reduce patient risk, has acquired Atlanta, Georgia-based NeuroLink Monitoring, expanding its coverage to seven East Coast States -- New York, New Jersey, North Carolina, South Carolina, Georgia, Alabama, and Florida.

While biologic medications have revolutionized the treatment of chronic diseases and conditions, reports show approximately 50 percent of medications for chronic disease are not taken as prescribed. It’s a situation that providers, payers and pharmaceutical companies are trying to change, and a breakthrough needle-free drug delivery system from Portal Instruments that uses technology out of MIT to allow patients to easily manage their chronic conditions at home could help.

The U.S. Food and Drug Administration today approved a remote feature for follow-up programming sessions for the Nucleus Cochlear Implant System through a telemedicine platform. The remote programming feature is indicated for patients who have had six months of experience with their cochlear implant sound processor and are comfortable with the programming process.  

The sense of touch is often taken for granted. For someone without a limb or hand, losing that sense of touch can be devastating. While highly sophisticated prostheses with complex moving fingers and joints are available to mimic almost every hand motion, they remain frustratingly difficult and unnatural for the user. This is largely because they lack the tactile experience that guides every movement. This void in sensation results in limited use or abandonment of these very expensive artificial devices. So why not make a prosthesis that can actually "feel" its environment?  

EpicMD,, a trusted leader in cloud-based telehealth and telemedicine technology platforms, today announced the appointment of Jack Karabees as EpicMD’s President and Vice President of Sales. Karabees has spent over 25 years successfully establishing and executing high-growth sales and marketing plans for enterprise healthcare, payer and hospital-related software technology companies. “We feel that Karabees brings an unusual blend of technology and healthcare leadership experience to the company,” said Matt Wanderer, company CEO. “His experience at this stage of company growth is also a fantastic fit,” he continued.

The TelePsy eHealth platform provides mental health professionals and general practitioners with digital tools to support them in the diagnostics, evaluation and treatment of their service users. Thanks to an integration with the secure Alterdesk Messenger, TelePsy can now offer its users chat and video call functionalities. “It is one of the biggest functional updates we have had in years”, says Marco Essed, CEO of TelePsy.

AMBOSS, a breakthrough medical study platform, today introduced its comprehensive test preparation and in-depth study tools for NBME® Subject Examinations (e.g., Shelf Exams) and USMLE™ Step 2 CK. More than 200,000 medical students and physicians worldwide rely on the AMBOSS platform for test preparation, in-depth studying, and as a clinical companion. AMBOSS is the only digital resource that includes more than 2,000 exam questions that are integrated with 15,000+ medical library topics. Specific Shelf Exam preparation is available for medicine, surgery, pediatrics, clinical neurology, obstetrics and gynecology, and psychiatry rotations.

During the weeks since Hurricanes Irma and Maria devastated the infrastructure of Puerto Rico, the U.S. Food and Drug Administration has joined federal and local agencies in the effort to help the people of Puerto Rico recover and begin to rebuild the island. Among the challenges the FDA has addressed is the potential for shortages of critical medical products. The FDA has been monitoring more than 40 drug products and working closely with dozens of pharmaceutical and medical device companies to help these important facilities get back online; enabling employees to return to work and manufacturers to ramp up production of medical products used by all Americans.

Bioprinting startup BIOLIFE4D named accomplished thoracic and cardiac surgeon Jeffrey Morgan M.D., FACS, FACC as Chief Medical Officer, further bolstering its world-class leadership team. BIOLIFE4D is a pioneering biotech company focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant.

Significantly fewer African-Americans, Hispanics, Asians and non-Hispanic whites say ‘lack of trust’ is a reason why individuals do not participate in clinical trials, indicating a more favorable perception of this research. In a recent public opinion survey commissioned by Research!America, the percentage of respondents citing ‘lack of trust’ as a reason declined by as much as 15% among minority groups and the population overall, compared to the results of a 2013 survey – 50% of African-Americans (11% decrease), 45% of Asians (6% decrease), 43% of Hispanics (9% decrease) and 39% of non-Hispanic whites (15% decrease).

The Qt Company (HEX: QTCOM) today announced it will become a member of leading medical technology professional organizations AdvaMed and MassMEDIC, stepping into the integral role of industry advisor and enabler of technology innovation. In this role, Qt will influence the direction of the standards and regulations that govern the medical device industry on a global scale, and will help introduce new medical device technology advancements.

Mount Sinai researchers have identified unique structural, biological and chemical insights in the way different opioid drugs activate the receptors and specific signaling pathways responsible for the drug’s beneficial and adverse effects, according to a study to be published in Nature’s Scientific Reports. 

Independent healthcare accreditor URAC and Telemedicine Magazine will host the Telemed Leadership Forum 2018: ROI of TelehealthMarch 27 – 29, 2018 at the Renaissance Washington, DC.